

# **Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/I250EFFC030EN.html>

Date: October 2018

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: I250EFFC030EN

## **Abstracts**

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018

### **SUMMARY**

According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018'; Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of auto reactive T-cells.

The report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018' outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 3, 5 and 1 respectively. Report covers products from therapy areas Immunology, Oncology and

Cardiovascular which include indications Non-Small Cell Lung Cancer, Autoimmune Disorders, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Solid Tumor, Stroke and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -  
Overview

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -  
Companies Involved in Therapeutics Development

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug  
Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APT-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab biobetter - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
CC-92252 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
daclizumab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
darleukin - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
daromun - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
MDNA-209 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
NARA-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
NKTR-358 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

teleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones

Featured News & Press Releases

Sep 11, 2018: Alkermes expands Phase I trial of ALKS 4230 for advanced solid tumors

Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma

May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits

May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus

Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders

Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta

Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis

Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage

Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting

Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta

Appendix

Methodology

[Coverage](#)  
[Secondary Research](#)  
[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Alkermes Plc, H2 2018  
Pipeline by Celgene Corp, H2 2018  
Pipeline by Medicenna Therapeutics Corp, H2 2018  
Pipeline by Nektar Therapeutics, H2 2018  
Pipeline by Philogen SpA, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

## I would like to order

Product name: Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/I250EFFC030EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I250EFFC030EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

